An overview of the various appropriate types of cell lines for the
production of monoclonal antibodies
Abstract
As the first monoclonal antibodies were produced in 1975, the challenge
to improve antibody engineering started. Since then, therapeutic
antibodies have become the predominant class of new drugs developed in
recent years and an essential part of progress has affected cell lines.
From the first pioneer hybridoma cells to the current vanguard Chinese
hamster ovary [CHO] cells dramatic improvement has been seen. An
essential part of this process is choosing the suitable cell line to
seed the targeted antibody gene. This review encompasses all the current
evidence to compare various types of suitable cell lines for monoclonal
antibody production such as mammalian cells, plant cells, bacterial
cells, and yeast cells. Valid long-term data, regarding glycosylation,
efficiency, and safety, support the current popularity of Chinese
hamster ovary [CHO] cells. At the same time, other types of cell
lines also show some promise for emerging needs for more therapeutic
antibodies on the market.